Novedades en el tratamiento antitrombótico en intervencionismo coronario

The aims of this paper are to analyze Clopidogrel response variability and its relationship to clinical outcome and to review the role of the new antiplatelet agents in coronary intervention. Clopidogrel antiplatelet effect is extremely variable and is hampered by drug interactions and genetic polymorphisms. Platelet function tests may indicate in the future which are the optimal platelet aggregation inhibition therapeutic range. Currently, there are no data supporting their clinical application. Prasugrel and Ticagrelor reduce thrombotic complications and even mortality in patients with acute coronary syndromes. Newer, abbreviated and intracoronary GP IIb/IIIa inhibitors infusions reduce haemorrhagic risk and show a similar benefit than the traditional ones.